How to buy Microchip Technology (MCHP) stock from India

Yes, an Indian resident can buy Microchip Technology — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%. The 90% is tax, estate exposure, and the dividend story — MCHP froze a long streak of payout growth during the worst inventory cycle in its history. This is the short version.

The 30-second version

• Legal and simple. Buy MCHP via Vested, INDmoney, Interactive Brokers or Rovia. Whole shares or a fractional rupee amount.
• Dividend story is the headline. MCHP pays 45.5 cents/quarter ($1.82 annualised) — but it has been frozen since late 2024 after years of raises, as FCF collapsed in the inventory bust. A frozen payout from a serial raiser is a red flag.
• India tax: dividends face 25% US withholding under the India-US DTAA; gains held more than 24 months pay 12.5% LTCG (Section 112, no indexation); sooner = slab.
• The trap most miss: directly-held MCHP is a US-situs asset — above $60,000, the estate faces up to 40% US estate tax with no treaty relief.
• If your thesis is "analog and embedded chips," SOXX and SMH already hold MCHP alongside ADI, TXN and ON — same cycle exposure, no single-stock risk.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	MCHP / Nasdaq
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share (fractional lets you invest an exact rupee amount)
Dividend	About 45.5 cents per quarter, frozen since late 2024 after years of compounding raises
India tax on gains	12.5% LTCG after 24 months; else your slab (Section 112)
Estate-tax risk	US-situs above $60k means up to 40%, no treaty relief
Annual compliance	Schedule FA disclosure plus Form 67 for any dividend FTC, every year you hold

How to buy it — 3 steps

1. Open an account and finish KYC. Pick an India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). File your W-8BEN during onboarding so dividend withholding drops from the 30% statutory rate to the 25% treaty rate. New here? Start with how to invest in US stocks from India.
2. Fund via the LRS. Remit under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. MCHP trades in the $55-75 range through 2025, so a whole share is affordable; fractional buys let you size in rupees.

The dividend story — read this twice

Microchip ran one of the cleanest dividend-growth records in semis for over a decade. Then the inventory cycle hit. Through fiscal 2025 revenue fell more than 40% from peak as industrial and auto customers worked through 12-plus months of inventory, free cash flow turned negative in the trough, and the dividend stopped growing. The payout has been flat at roughly 45.5 cents per quarter (~$1.82 annualised) since late 2024 — the first time in years it hasn't ticked up.

It is not a cut. But for a name whose entire pitch was "raise every quarter," a freeze is the soft version: cash flow wasn't safe, and management chose to defend the balance sheet (still carrying net debt from the 2018 Microsemi deal) over further raises. Treat the yield as provisional.

On tax, dividends face 25% US withholding under the India-US treaty (W-8BEN gets this rate). The full dividend is added to your Indian taxable income at slab; you reclaim the US 25% as a Foreign Tax Credit by filing Form 67 before your ITR. From AY 2026-27 the FTC schema migrates to Form 44. Full mechanics in dividend withholding and Form 67.

The capital-gains tax that actually matters

Your bigger exposure is capital gains at sale, under Section 112 (foreign shares don't get the friendlier Section 112A treatment Indian equity gets):

Holding period	Treatment	Rate
24 months or less	Short-term	Slab (up to ~30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 30 shares at $60 when USD/INR is 86 → cost 1,54,800 rupees. Sell 28 months later at $72 when USD/INR is 88 → proceeds 1,90,080 rupees. Taxable gain 35,280 rupees; LTCG at 12.5% = 4,410 rupees. Gain is computed in rupees, so a weaker rupee at sale amplifies your reported gain. Model your own with the US capital-gains calculator.

The $60,000 estate-tax trap

Directly-held MCHP is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax, so there's no credit. The fix (holding through pooled or fund structures rather than direct shares) has to be a deliberate choice made before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get Microchip through an ETF?

If you want…	Best route
A concentrated bet on MCHP beating peer analog and MCU names	MCHP directly
"Semis cycle bottoming" exposure	SOXX or SMH — MCHP sits alongside TXN, ADI, NXP, ON
Broad US tech with some MCHP	QQQ — tiny MCHP weight, wider safety net
Pure-play analog or MCU index	None worth recommending — analog-only ETFs are thinly traded

SOXX and SMH give MCHP plus its closest competitors in one Schedule FA line and cleaner estate treatment — but the bulk is now AI/GPU names like Nvidia and Broadcom, so the cycle exposure is diluted. Compare in direct stocks vs US ETFs and best US ETFs for Indian investors; broader case in US ETFs for Indians.

The business in one screen

What it is: Microchip is one of the world's three big embedded-control franchises, alongside Texas Instruments and STMicroelectronics. It sells MCUs, analog, FPGAs, memory and connectivity into industrial, automotive, aerospace-and-defence, and data-centre customers — a capex-light model built around a total-system-solution pitch (the more Microchip parts a designer uses, the harder switching becomes).

Bull case	Bear case
Inventory cycle bottoming, bookings inflecting	Post-Microsemi net debt limited dividend flexibility
Capex-light analog model — durable margins through cycle	Industrial customers slower to come back than auto
Total-system-solution selling deepens design wins	Chinese low-end MCU competitors (GigaDevice, Espressif)
Modest China revenue mix — less geopolitical exposure	Lost share to ST Micro and Renesas during the shortage
Path to restoring dividend growth as FCF recovers	Stock rallied on hope; valuation no longer cycle-low

Exact valuation is in the live widget above — a cyclical compounder priced for a recovery that is happening but not complete.

Our take

Verdict: HOLD — the cycle is bottoming and the model is sound, but the rally has run ahead of the earnings recovery and the frozen dividend remains an unresolved signal.

• Bottoming, not booming. Bookings have inflected, but revenue and gross-margin recovery still lags the share-price rally.
• The dividend pause matters. Microchip's investor base was built on quarterly raises. The freeze since late 2024 tells you FCF wasn't comfortably covering the payout in the trough. A restoration of raises is the cleanest signal the cycle is genuinely behind them.
• Better entry on a re-test, not on hope. Bull case (capex-light analog, total-system-solution moat, modest China exposure) is real; so is bear (share lost to ST Micro and Renesas in the shortage, low-end Chinese MCU intensity, valuation premium on cycle-low earnings). We'd rather see a re-test of cycle lows than chase the rally.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• Dividend re-cut risk: if the cycle stalls, a frozen dividend can become a reduced one. Size MCHP assuming the yield could fall, not that it grows back on a straight line.
• China low-end MCU competition: GigaDevice, Espressif and others price aggressively in the 32-bit MCU segment Microchip historically owned. Share losses here dent the recovery thesis.
• Currency: returns are in USD, you spend rupees — see the rupee-dollar effect.

Two things people forget

• Schedule FA and Form 67: disclose MCHP in Schedule FA of your ITR every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. Separately, file Form 67 (Form 44 from AY 2026-27) before your ITR each year you receive a dividend, to claim FTC for the 25% US withholding. Use the Schedule FA helper.
• Position size: semis are cyclical and Microchip is mid-cap globally. Size it as a high-conviction satellite within a semis sleeve, not a broad-ETF substitute.

Bottom line

Buying MCHP from India is easy and legal. What needs thought: MCHP is a Section-112 capital-gains play (12.5% after 24 months), a dividend payer with 25% US withholding and annual Form 67, a US-situs asset with a $60k estate trap, and a cyclical name whose dividend pause tells you the cycle was very real. If your thesis is "the analog and embedded cycle is turning," a semis ETF gives the same exposure with less single-name dividend-policy risk. For accounts and options, start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.